New York State Teachers Retirement System Buys 1,432 Shares of Omnicell, Inc. (NASDAQ:OMCL)

New York State Teachers Retirement System lifted its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 2.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 61,974 shares of the company’s stock after acquiring an additional 1,432 shares during the quarter. New York State Teachers Retirement System owned 0.13% of Omnicell worth $2,759,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock worth $64,573,000 after acquiring an additional 699,925 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after acquiring an additional 1,138,921 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its holdings in shares of Omnicell by 27.1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after acquiring an additional 243,353 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Omnicell by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock worth $48,176,000 after acquiring an additional 2,877 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Omnicell by 3.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 594,996 shares of the company’s stock worth $25,942,000 after acquiring an additional 22,198 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Omnicell Trading Up 0.2 %

NASDAQ:OMCL opened at $39.72 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The company has a fifty day moving average of $43.09 and a 200 day moving average of $43.85. The firm has a market capitalization of $1.84 billion, a P/E ratio of 147.12, a P/E/G ratio of 7.62 and a beta of 0.78. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, research analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on OMCL. Craig Hallum boosted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Benchmark reiterated a “buy” rating and set a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. upped their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Finally, Wells Fargo & Company lowered their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Omnicell currently has an average rating of “Hold” and a consensus target price of $52.33.

Insider Buying and Selling at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.64% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.